Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Shots:  Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that leads to the progressive degeneration of nerve cells in the spinal cord and brain  Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…
February 25, 2025
EMA Marketing Authorization of New Drugs in January 2025
EMA Marketing Authorization of New Drugs in January 2025
Shots:    The EMA’s CHMP has granted positive opinions to 5 Biologics in January 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Merck’s Capvaxive to treat Pneumococcal Disease  PharmaShots has compiled a list of 4 drugs that have been granted positive opinions and approvals by the EMA’s…
February 18, 2025
The US FDA New Drug Approvals in January 2025
The US FDA New Drug Approvals in January 2025
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of January 2025       The US FDA has approved a total of 3 new drug including 2 new molecular entities and 1 biologic leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was Daiichi Sankyo &…
February 11, 2025
Know Your Investor: Orbimed (February’ 25 Edition)
Know Your Investor: Orbimed (February’ 25 Edition)
Shots:    The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors  In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing  For the complete report, contact us at connect@pharmashots.com  OrbiMed primarily…
February 6, 2025
A Complete Account of FDA Approvals in 2024
A Complete Account of FDA Approvals in 2024
Shots: In 2024, around 50 new drugs were approved by the US FDA across several indications PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Hematology, Dermatology, and Cardiology For the complete report with analysis, reach out to us at  connect@pharmashots.com   While you embraced the new…
February 5, 2025
Key Biosimilars Events of January 2025
Key Biosimilars Events of January 2025
Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the Samsung Bioepis & Teva Partners to Commercialize Epysqli in…
February 4, 2025
New Drug Designations - December 2024
New Drug Designations – December 2024
Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA   The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others  Significant…
January 31, 2025
Key Takeaways of J.P. Morgan Healthcare Conference 2025
Key Takeaways of J.P. Morgan Healthcare Conference 2025
Shots:  The 43rd Annual J.P. Morgan Conference took place from 13th to 16th January in San Francisco, USA. J.P. Morgan Healthcare Conference serves as a pioneering hub that features presentations and dialogues on the advances of the healthcare industry by bringing healthcare professionals, researchers, manufacturers, and other healthcare stakeholders to one platform.   Innovation remained the…
January 28, 2025
EMA Marketing Authorization of New Drugs in December 2024
EMA Marketing Authorization of New Drugs in December 2024
Shots:    The EMA’s CHMP has granted positive opinions to 5 Biologics and 4 New Chemical Entities in December 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Galderma’s Nemluvio to treat Prurigo Nodularis and Atopic Dermatitis    PharmaShots has compiled a list of 9 drugs that have been granted positive…
January 23, 2025
Disease of the Month – Epilepsy
Disease of the Month – Epilepsy
Shots:  Epilepsy is a chronic, non-communicable brain condition that affects neurons and causes recurring seizures Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry players advancing treatments for epilepsy For a detailed analysis and tailored…
January 21, 2025
Load more